Portland, OR, Sept. 02, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global schizophrenia drugs market generated $7.16 billion in 2021 and is estimated to hit $12.53 billion by 2031, registering a CAGR of 5.8% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario. The report is a helpful source of information for leading market players, new entrants, investors, and stakeholders in devising strategies for the future and taking steps to strengthen their position in the market.
Download Sample Report- https://www.alliedmarketresearch.com/request-sample/17470
Report coverage & details:
| Report Coverage | Details |
| Forecast Period | 2022–2031 |
| Base Year | 2021 |
| Market Size in 2021 | $7.16 billion |
| Market Size in 2031 | $12.53 billion |
| CAGR | 5.8% |
| No. of Pages in Report | 220 |
| Segments covered | Treatment, Distribution Channel, Therapeutic Class, and Region |
| Drivers | Increase in prevalence of schizophrenia and mental disturbances such as anxiety and depression |
| Rise in awareness about mental health and schizophrenia treatments, and increase in acceptability of schizophrenia drugs by medical practitioners | |
| Surge in mental health awareness programs by government and non-government organizations | |
| Rise in number of geriatric population | |
| Opportunities | Increase in R&D activity for advancements in anti-psychotic drugs and number of product launches and approvals |
| Rise in number of clinical trials for the development of novel schizophrenia treatments | |
| Rise in number of industrial collaborations in drug development | |
| Restraints | Lack of appropriate healthcare infrastructure for mental health |
Impact of Covid-19 on Schizophrenia Drugs Market-
- The Covid-19 outbreak negatively impacted the global schizophrenia drugs market. Due to implementation of lockdowns and imposition of stringent measures by governments across the globe, production and manufacturing activities came to a halt.
- The pharmaceutical industry faced difficulties in focusing on R&D activities regarding schizophrenia drugs development as the entire healthcare industry was focused on life saving and COVID-19 related products.
- There were delays in product approvals and launches which further restricted the expansion of the market. Furthermore, most of the clinical trials were postponed to avoid spread of infections, thus slowing down the drug development process.
- However, the pandemic led to the increase in mental health problems worldwide and the healthcare sector has been restructured to provide safer healthcare facilities. Hence, the schizophrenia drugs market is anticipated to grow in the coming years.
Get detailed COVID-19 impact analysis on the Schizophrenia Drugs Market- https://www.alliedmarketresearch.com/request-for-customization/17470?reqfor=covid
The report offers detailed segmentation of the global schizophrenia drugs market based on treatment, distribution channel, therapeutic class, and region. The report provides an analysis of each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors, and new entrants in determining the sub-segments to be tapped on to achieve growth in the coming years.
Based on treatment, the oral segment accounted for nearly three-fourths of the global schizophrenia drugs market share in 2021, and is expected to maintain its dominance during the forecast period. However, the injectable segment would cite the fastest CAGR of 6.2% throughout 2031.
Based on distribution channel, the retail pharmacies segment contributed to nearly half of the total schizophrenia drugs market in 2021, and is expected to rule the roost by 2031. The online pharmacies segment, on the other hand, would grow at the highest CAGR of 7.5% by 2031.
Based on therapeutic class, the second generation segment contributed to nearly three-fourths of the total schizophrenia drugs market in 2021, and would lead the trail through the forecasted timeframe. However, the third generation segment would grow at the fastest CAGR of 6.2% from 2022 to 2031.
Based on region, the market across North America contributed to nearly half of the global schizophrenia drugs market in 2021, and would maintain its leadership status during the forecast period. On the other hand, Asia-Pacific would grow at the fastest CAGR of 7.3% from 2022 to 2031. The other two provinces discussed in the report include Europe and LAMEA.
For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/17470
The key market players analyzed in the global schizophrenia drugs market report include Pfizer Inc., AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck KGAA, Minerva Neurosciences, Novartis AG, Reliance, Sumitomo Dainippon, Takeda Pharmaceuticals, Vanda Pharmaceuticals, and Alkermes.
The report analyzes these key players of the global schizophrenia drugs market. These players have adopted various strategies such as expansion, new product launches, partnerships, and others to increase their market penetration and strengthen their position in the industry. The report is helpful in determining the business performance, operating segments, product portfolio, and developments by every market player.
Official Press Release - https://www.alliedmarketresearch.com/press-release/schizophrenia-drugs-market.html
Trending Reports in Healthcare Industry-
Ulcerative Colitis Market - Global Opportunity Analysis and Industry Forecast, 2020-2030
Orthopedic Implants Market - Global Opportunity Analysis and Industry Forecast, 2020–2030
3D Printed Drugs Market- Global Opportunity Analysis and Industry Forecast, 2020–2030
Wearable Injectors Market - Global Opportunity Analysis and Industry Forecast, 2020–2030
Computed Tomography (CT) Market - Global Opportunity Analysis and Industry Forecast, 2020–2030
Empty Capsules Market - Global Opportunity Analysis and Industry Forecast, 2020–2030
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter
